Acadia Pharmaceuticals | ACAD - Gross Profit On Sales



Acadia Pharmaceuticals reported $243.83M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.


Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.83M 19.91M Jun/2025
ALKERMES USD 257.77M 462K Jun/2025
Alnylam Pharmaceuticals USD 630.74M 107.59M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
BioMarin Pharmaceutical USD 670.47M 76.89M Jun/2025
Bristol-Myers Squibb USD 8.9B 714M Jun/2025
Corcept Therapeutics USD 191M 36.19M Jun/2025
Cytokinetics 66.77M 165.03M Jun/2025
Eisai JPY 160.05B 12.42B Jun/2025
Eli Lilly USD 13.11B 2.61B Jun/2025
Incyte USD 1.14B 151.67M Jun/2025
J&J USD 14.6B 816M Mar/2025
Moderna USD 18M 1000K Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Pfizer USD 10.88B 248M Jun/2025
Prothena -36100000 22.9M Jun/2025
PTC Therapeutics USD 163.39M 999.84M Jun/2025
Sarepta Therapeutics USD 457.87M 149.43M Jun/2025
Ultragenyx Pharmaceutical USD 143.49M 32.86M Jun/2025
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025